Carol Laherty

Cooley advised Archon Biosciences, a biotechnology company pioneering computationally designed antibody cages (AbCs) to unlock powerful therapeutic targets beyond the reach of existing modalities, on its $20 million seed financing led by Madrona Ventures.

New York – Cooley advised the underwriters on Egalet's initial public offering. Egalet is a specialty pharmaceutical company that develops and plans to commercialize abuse-deterrent oral products. Egalet now trades on the Nasdaq Global Market under the symbol "EGLT."

Stifel Nicolaus and JMP Securities acted as joint book-running managers for the offering. Canaccord Genuity and Janney Montgomery Scott acted as co-managers.

This offering follows Cooley's record year in 2013 for capital markets in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion. Year-to-date in 2014, Cooley has advised on 22 completed public offerings, including 12 completed IPOs.

San Francisco – Cooley advised the underwriters on Epizyme's recent IPO. Epizyme, now trading on the Nasdaq Global Stock Market under the symbol "EPZM," is a Massachusetts based biopharmaceutical company that discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers.

Citigroup Global Markets, Cowen and Co. and Leerink Swann acted as lead joint book-running managers for the offering. JMP Securities and Wedbush Securities acted as co-managers.

Based on the American Lawyer's 2012 Corporate Scorecard, Cooley served as issuer counsel on 40 total US equity offerings, ranking as the most active law firm advising issuers in the country. Cooley was also the third most active law firm advising underwriters on US IPOs.